Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Receives Consensus Recommendation of “Hold” from Analysts

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has earned a consensus rating of “Hold” from the twelve brokerages that are currently covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a sell recommendation, five have given a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $26.57.

A number of equities research analysts have recently commented on VNDA shares. Zacks Investment Research upgraded shares of Vanda Pharmaceuticals from a “hold” rating to a “buy” rating and set a $14.00 price target for the company in a report on Friday, August 2nd. Oppenheimer set a $18.00 price target on shares of Vanda Pharmaceuticals and gave the stock a “hold” rating in a report on Sunday, May 5th. ValuEngine upgraded shares of Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Citigroup upgraded shares of Vanda Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $19.00 price target for the company in a report on Thursday, August 1st. Finally, Stifel Nicolaus reiterated a “hold” rating and set a $17.00 price target on shares of Vanda Pharmaceuticals in a report on Wednesday, July 31st.

VNDA traded up $0.08 during midday trading on Friday, reaching $14.88. 12,318 shares of the company’s stock were exchanged, compared to its average volume of 912,405. The firm has a market cap of $801.24 million, a PE ratio of 30.96 and a beta of 0.38. The company’s 50-day moving average price is $13.87. Vanda Pharmaceuticals has a 1-year low of $11.83 and a 1-year high of $33.44.



Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its earnings results on Wednesday, July 31st. The biopharmaceutical company reported $0.21 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.24. The company had revenue of $59.06 million during the quarter, compared to analysts’ expectations of $54.19 million. Vanda Pharmaceuticals had a net margin of 13.61% and a return on equity of 10.23%. The firm’s quarterly revenue was up 24.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.15 earnings per share. On average, analysts anticipate that Vanda Pharmaceuticals will post 0.32 EPS for the current year.

In related news, CEO Mihael Hristos Polymeropoulos sold 72,872 shares of the business’s stock in a transaction that occurred on Tuesday, May 21st. The shares were sold at an average price of $15.34, for a total value of $1,117,856.48. Following the completion of the sale, the chief executive officer now directly owns 1,276,343 shares in the company, valued at $19,579,101.62. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 8.20% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in the stock. Advisor Group Inc. lifted its position in Vanda Pharmaceuticals by 66.2% during the fourth quarter. Advisor Group Inc. now owns 2,916 shares of the biopharmaceutical company’s stock valued at $77,000 after buying an additional 1,161 shares in the last quarter. Pearl River Capital LLC lifted its position in Vanda Pharmaceuticals by 6,148.0% during the first quarter. Pearl River Capital LLC now owns 6,248 shares of the biopharmaceutical company’s stock valued at $114,000 after buying an additional 6,148 shares in the last quarter. O Shaughnessy Asset Management LLC acquired a new position in Vanda Pharmaceuticals during the first quarter valued at approximately $117,000. Adams Diversified Equity Fund Inc. acquired a new position in Vanda Pharmaceuticals during the first quarter valued at approximately $120,000. Finally, Pacer Advisors Inc. acquired a new position in Vanda Pharmaceuticals during the second quarter valued at approximately $138,000. Hedge funds and other institutional investors own 99.33% of the company’s stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.

Recommended Story: Equal Weight Rating

Analyst Recommendations for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.